Skip to main content

24-02-2022 | ASCO GU 2022 | Conference coverage | Video

Support for continuing enzalutamide after mCRPC progression

share
SHARE

Axel Merseburger discusses the results of the PRESIDE trial of enzalutamide rechallenge in metastatic castration-resistant prostate cancer in the context of the current treatment landscape, and outlines unanswered questions (4:35).